Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with South Korea-headquartered LegoChem Biosciences, Inc. Under this agreement, the two companies will leverage LaNova’s antibody assets and LCB’s antibody-drug conjugate (ADC) technology platform to develop an innovative ADC product.
LaNova Medicines: A Clinical-Stage R&D Company
Established in 2019, LaNova Medicines is a clinical-stage R&D company focused on the development of macromolecular anti-tumor drugs using GPCRs for monoclonal antibody production. The company has a differentiated product pipeline that includes four clinical-stage drugs targeting CCR8, GPRC5D, Claudin 18.2, and SIRPα.
LM-302: A Notable ADC Product
LaNova Medicines’ LM-302, a Claudin 18.2-targeted ADC with orphan drug designations (ODDs) for use in pancreatic cancer, gastric cancer, gastroesophageal junction cancer, and cholangiocarcinoma in the US, was licensed to US firm Turning Point Therapeutics, Inc. (TPTX.US) in May last year. The deal was valued at USD 1 billion for the global market, excluding Greater China and South Korea.
LM-108 and LM-305: Clinical Trials and Firsts
LM-108, an in-house developed monoclonal antibody (mAb) targeting CCR8, obtained approval for clinical trials in China in May 2022. LM-305, which received nods for studies in the US and China in July and November 2022 respectively, is currently the world’s first and only drug of its kind approved for clinical trials.-Fineline Info & Tech
